Trials / Completed
CompletedNCT07053852
Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and Photodamage
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Sherrif Ibrahim · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
To provide a treatment of both actinic keratoses and photodamage within one treatment.
Detailed description
To demonstrate that treatment of actinic keratoses and photodamage with a combination of Ameluz and Broad Band Light (BBL) will lead to an improvement in facial precancerous change and signs of photodamage.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ameluz | broad band light (BBL) with the use of Ameluz |
| DEVICE | Sciton HEROic | Each subject will receive 2 treatments of photodynamic therapy using Ameluz and HEROic BBL to treat facial AK and signs of photodamage. |
Timeline
- Start date
- 2025-06-27
- Primary completion
- 2025-12-29
- Completion
- 2025-12-29
- First posted
- 2025-07-08
- Last updated
- 2026-01-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT07053852. Inclusion in this directory is not an endorsement.